<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601105</url>
  </required_header>
  <id_info>
    <org_study_id>637397</org_study_id>
    <nct_id>NCT02601105</nct_id>
  </id_info>
  <brief_title>Topical Centella Asiatica and the Cosmetic Appearance of Stretch Marks</brief_title>
  <official_title>Topical Centella Asiatica and the Cosmetic Appearance of Stretch Marks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to clinically evaluate the efficacy, safety as well as patient&#xD;
      satisfaction in the use of topical Centella asiatica (CA) on the cosmetic appearance of&#xD;
      stretch marks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with abdominal stretch marks will be enrolled in to this study. The presence of&#xD;
      abdominal stretch marks will be confirmed by a board certified dermatologist. The right and&#xD;
      the left side of the abdomen will be randomized by binary randomization to treatment with CA&#xD;
      cream or the vehicle cream. Therefore each patient will serve as their own control.&#xD;
&#xD;
      Each half of the abdomen will be subjected to topical treatment with CA 1% Cream formulated&#xD;
      in PCCA Lipoderm® base or PCCA Lipoderm® base as the placebo vehicle treatment based on prior&#xD;
      randomization. The creams will be given to the patient in blinded fashion: Cream A&#xD;
      (containing CA) and cream B (vehicle/placebo) with instructions apply both formulations daily&#xD;
      at night.&#xD;
&#xD;
      Patients will be asked to return to clinic at 6 weeks and 12 weeks for follow up assessment&#xD;
      for a total of 3 sessions (baseline, 6 weeks, 12 weeks). High-resolution digital photographs&#xD;
      of the stretch marks will be taken at baseline and at each follow-up visit to document&#xD;
      clinical response. Two physician graders blinded to the photographs and the treatments will&#xD;
      assess cosmetic outcome on a six-point analog scale&#xD;
&#xD;
      The width of the treated stretch marks in each subject will also be measured at the baseline&#xD;
      and 8 weeks after the final treatment. The difference of the width will be converted into the&#xD;
      percentage of reduction from the baseline.&#xD;
&#xD;
      Subjects will also be asked to complete two surveys at each visit. The two surveys include&#xD;
      patient satisfaction with cosmetic and clinical outcome based on a five-point scale.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>15 patients were enrolled. All 15 patients had one side of abdomen randomized to placebo and one randomized to Centella Asiatica.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cosmetic Outcome- Fraction Improving by at Least 1 Point Increase in Overall Appearance of Stretch Marks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessed by four blinded evaluators by observing comparative baseline photographs using 6 point scale (worsened = -1 points, no improvement = 0 points, mild = 1 points, &lt;25% improvement, moderate = 2 points, 26-50% improvement, good = 3 points, 51-75% improvement, excellent = 4 points, &gt;75% improvement)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stretch Mark Width/Area</measure>
    <time_frame>12 weeks</time_frame>
    <description>Stretch mark width: measured at week 12. This will be converted into the percentage of reduction from the baseline.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Stretch Marks</condition>
  <condition>Striae Distensae</condition>
  <condition>Cosmetic Appearance of Stretch Marks</condition>
  <arm_group>
    <arm_group_label>Placebo Vehicle Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lipoderm® base served as the placebo vehicle control to be applied every night to demarcated 10 x 10 cm area containing stretch marks on randomly assigned side of abdomen for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Centella Asiatica Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An alcoholic extract of CA (verified by HPLC) mixed into a Lipoderm® base served as the treatment cream to be applied every night to demarcated 10 x 10 cm area containing stretch marks on the opposite side of the abdomen for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Vehicle Cream</intervention_name>
    <description>Lipoderm Cream alone</description>
    <arm_group_label>Placebo Vehicle Cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Centella Asiatica Cream</intervention_name>
    <description>1% Centella Asiatica in lipoderm</description>
    <arm_group_label>Centella Asiatica Cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. English-speaking subjects over the age of 18&#xD;
&#xD;
          2. Subjects clinically diagnosed with stretch marks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of keloid scarring&#xD;
&#xD;
          2. Isotretinoin use within the last 6 months&#xD;
&#xD;
          3. Oral prednisone use within the last 3 months&#xD;
&#xD;
          4. Non-ablative laser procedures to the abdomen within 1 year of study initiation&#xD;
&#xD;
          5. Ablative resurfacing procedures to the abdomen within 3 years of the study initiation&#xD;
&#xD;
          6. Pregnancy&#xD;
&#xD;
          7. Use of immunosuppressive drugs&#xD;
&#xD;
          8. Known hypersensitivity to Centella asiatica&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raja K Sivamani, MD, MS, CAT</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Davis Department of Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cho S, Park ES, Lee DH, Li K, Chung JH. Clinical features and risk factors for striae distensae in Korean adolescents. J Eur Acad Dermatol Venereol. 2006 Oct;20(9):1108-13.</citation>
    <PMID>16987267</PMID>
  </reference>
  <reference>
    <citation>Brinkhaus B, Lindner M, Schuppan D, Hahn EG. Chemical, pharmacological and clinical profile of the East Asian medical plant Centella asiatica. Phytomedicine. 2000 Oct;7(5):427-48. Review.</citation>
    <PMID>11081995</PMID>
  </reference>
  <reference>
    <citation>Incandela L, Cesarone MR, Cacchio M, De Sanctis MT, Santavenere C, D'Auro MG, Bucci M, Belcaro G. Total triterpenic fraction of Centella asiatica in chronic venous insufficiency and in high-perfusion microangiopathy. Angiology. 2001 Oct;52 Suppl 2:S9-13. Review.</citation>
    <PMID>11666128</PMID>
  </reference>
  <reference>
    <citation>Lu L, Ying K, Wei S, Fang Y, Liu Y, Lin H, Ma L, Mao Y. Asiaticoside induction for cell-cycle progression, proliferation and collagen synthesis in human dermal fibroblasts. Int J Dermatol. 2004 Nov;43(11):801-7.</citation>
    <PMID>15533060</PMID>
  </reference>
  <reference>
    <citation>Rosen H, Blumenthal A, McCallum J. Effect of asiaticoside on wound healing in the rat. Proc Soc Exp Biol Med. 1967 May;125(1):279-80.</citation>
    <PMID>6027541</PMID>
  </reference>
  <reference>
    <citation>Sunilkumar, Parameshwaraiah S, Shivakumar HG. Evaluation of topical formulations of aqueous extract of Centella asiatica on open wounds in rats. Indian J Exp Biol. 1998 Jun;36(6):569-72.</citation>
    <PMID>9731470</PMID>
  </reference>
  <results_reference>
    <citation>Güngör S, Sayilgan T, Gökdemir G, Ozcan D. Evaluation of an ablative and non-ablative laser procedure in the treatment of striae distensae. Indian J Dermatol Venereol Leprol. 2014 Sep-Oct;80(5):409-12. doi: 10.4103/0378-6323.140296.</citation>
    <PMID>25201840</PMID>
  </results_reference>
  <results_reference>
    <citation>Mazzarello V, Farace F, Ena P, Fenu G, Mulas P, Piu L, Rubino C. A superficial texture analysis of 70% glycolic acid topical therapy and striae distensae. Plast Reconstr Surg. 2012 Mar;129(3):589e-590e. doi: 10.1097/PRS.0b013e3182419c40.</citation>
    <PMID>22374035</PMID>
  </results_reference>
  <results_reference>
    <citation>García Hernández JÁ, Madera González D, Padilla Castillo M, Figueras Falcón T. Use of a specific anti-stretch mark cream for preventing or reducing the severity of striae gravidarum. Randomized, double-blind, controlled trial. Int J Cosmet Sci. 2013 Jun;35(3):233-7. doi: 10.1111/ics.12029. Epub 2013 Jan 15.</citation>
    <PMID>23237514</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 6, 2015</study_first_submitted>
  <study_first_submitted_qc>November 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2015</study_first_posted>
  <results_first_submitted>March 30, 2017</results_first_submitted>
  <results_first_submitted_qc>May 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 4, 2021</results_first_posted>
  <last_update_submitted>May 2, 2021</last_update_submitted>
  <last_update_submitted_qc>May 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gotu kola</keyword>
  <keyword>centella asiatica</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Striae Distensae</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The right and the left side of the abdomen were randomized by binary randomization to treatment with CA cream or the vehicle cream. Therefore each patient will serve as their own control.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>Placebo Vehicle Cream: Lipoderm Cream Alone Lipoderm® base served as the placebo vehicle control to be applied every night to demarcated 10 x 10 cm area containing stretch marks on randomly assigned side of abdomen for 12 weeks.&#xD;
Centella Asiatica: 1% Centella Asiatica in Lipoderm Cream An alcoholic extract of CA (verified by HPLC) mixed into a Lipoderm® base served as the treatment cream to be applied every night to demarcated 10 x 10 cm area containing stretch marks on the opposite side of the abdomen for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Placebo Cream; Centella Asiatica Bsln.</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Placebo Cream; Centella Asiatica Week 6</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Placebo Cream; Centella Asiatica Week 12</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The right and the left side of the abdomen were randomized by binary randomization to treatment with CA cream or the vehicle cream. Therefore each patient will serve as their own control.</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Placebo Vehicle Cream: Lipoderm Cream Alone&#xD;
Lipoderm® base served as the placebo vehicle control to be applied every night to demarcated 10 x 10 cm area containing stretch marks on randomly assigned side of abdomen for 12 weeks.&#xD;
Centella Asiatica: 1% Centella Asiatica in Lipoderm Cream&#xD;
An alcoholic extract of CA (verified by HPLC) mixed into a Lipoderm® base served as the treatment cream to be applied every night to demarcated 10 x 10 cm area containing stretch marks on the opposite side of the abdomen for 12 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Side of Abdomen</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.5" lower_limit="24" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cosmetic Outcome- Fraction Improving by at Least 1 Point Increase in Overall Appearance of Stretch Marks</title>
        <description>Assessed by four blinded evaluators by observing comparative baseline photographs using 6 point scale (worsened = -1 points, no improvement = 0 points, mild = 1 points, &lt;25% improvement, moderate = 2 points, 26-50% improvement, good = 3 points, 51-75% improvement, excellent = 4 points, &gt;75% improvement)</description>
        <time_frame>12 weeks</time_frame>
        <population>13 participants completed all study procedures and were included in data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Vehicle Cream</title>
            <description>Lipoderm® base served as the placebo vehicle control to be applied every night to demarcated 10 x 10 cm area containing stretch marks on randomly assigned side of abdomen for 12 weeks.&#xD;
Placebo Vehicle Cream: Lipoderm cream</description>
          </group>
          <group group_id="O2">
            <title>Centella Asiatica</title>
            <description>An alcoholic extract of CA (verified by HPLC) mixed into a Lipoderm® base served as the treatment cream to be applied every night to demarcated 10 x 10 cm area containing stretch marks on the opposite side of the abdomen for 12 weeks.&#xD;
Centella Asiatica: 1% Centella Asiatica in lipoderm</description>
          </group>
        </group_list>
        <measure>
          <title>Cosmetic Outcome- Fraction Improving by at Least 1 Point Increase in Overall Appearance of Stretch Marks</title>
          <description>Assessed by four blinded evaluators by observing comparative baseline photographs using 6 point scale (worsened = -1 points, no improvement = 0 points, mild = 1 points, &lt;25% improvement, moderate = 2 points, 26-50% improvement, good = 3 points, 51-75% improvement, excellent = 4 points, &gt;75% improvement)</description>
          <population>13 participants completed all study procedures and were included in data analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stretch Mark Width/Area</title>
        <description>Stretch mark width: measured at week 12. This will be converted into the percentage of reduction from the baseline.</description>
        <time_frame>12 weeks</time_frame>
        <population>13 participants completed all study procedures and were included in data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Vehicle Cream</title>
            <description>Lipoderm® base served as the placebo vehicle control to be applied every night to demarcated 10 x 10 cm area containing stretch marks on randomly assigned side of abdomen for 12 weeks.&#xD;
Placebo Vehicle Cream: Lipoderm cream</description>
          </group>
          <group group_id="O2">
            <title>Centella Asiatica</title>
            <description>An alcoholic extract of CA (verified by HPLC) mixed into a Lipoderm® base served as the treatment cream to be applied every night to demarcated 10 x 10 cm area containing stretch marks on the opposite side of the abdomen for 12 weeks.&#xD;
Centella Asiatica: 1% Centella Asiatica in lipoderm</description>
          </group>
        </group_list>
        <measure>
          <title>Stretch Mark Width/Area</title>
          <description>Stretch mark width: measured at week 12. This will be converted into the percentage of reduction from the baseline.</description>
          <population>13 participants completed all study procedures and were included in data analysis.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.05"/>
                    <measurement group_id="O2" value="0.87" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected during the study duration of 12 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Vehicle Cream</title>
          <description>Lipoderm® base served as the placebo vehicle control to be applied every night to demarcated 10 x 10 cm area containing stretch marks on randomly assigned side of abdomen for 12 weeks.&#xD;
Placebo Vehicle Cream: Lipoderm cream</description>
        </group>
        <group group_id="E2">
          <title>Centella Asiatica</title>
          <description>An alcoholic extract of CA (verified by HPLC) mixed into a Lipoderm® base served as the treatment cream to be applied every night to demarcated 10 x 10 cm area containing stretch marks on the opposite side of the abdomen for 12 weeks.&#xD;
Centella Asiatica: 1% Centella Asiatica in lipoderm</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Raja Sivamani MD</name_or_title>
      <organization>UC Davis Department of Dermatology</organization>
      <phone>916-703-5145</phone>
      <email>dermstudies@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

